<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001639'>Hypertrophic cardiomyopathy</z:hpo> (HCM) occurs in 1 in 500 individuals </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment options for HCM differ from those administered in <z:hpo ids='HP_0001677'>coronary disease</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and valvular disease patients that comprise the core of many cardiology practices </plain></SENT>
<SENT sid="2" pm="."><plain>In this article, we offer a concise summary of the therapeutic use of <z:chebi fb="0" ids="4657">disopyramide</z:chebi> for reducing gradients and relieving symptoms in obstructive HCM </plain></SENT>
</text></document>